Analyst Research

Report Title Price
NeoStem Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Thomson Reuters Stock Report - NEOSTEM, INC. (NBS-A)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Neostem, Inc. (NBS) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
ValuEngine Detailed Valuation Report for NBS
Provider: ValuEngine, Inc.
$127.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

NeoStem Inc Signs Definitive Merger Agreement To Acquire Amorcyte In Equity Transaction


Thursday, 14 Jul 2011 01:00pm EDT 

Neostem Inc. announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc. (Amorcyte), a development stage cell therapy company focusing on treatments for cardiovascular disease. Amorcyte's lead product candidate, AMR-001, is ready to initiate a Phase II study for the treatment of acute myocardial infarction (AMI). 

Latest Developments for NeoStem Inc

Latest Key Developments in Biotechnology

Company Quote

NeoStem Inc
(NBS)
0.59
0.02 +3.51%
24 May 2013